Mission | November 16, 2020
Depression is one of the most prevalent psychiatric disorders and a leading cause of disability worldwide, affecting an estimated 300 million people globally. Approximately one third of patients with major depressive disorder are diagnosed with treatment resistant depression. Symptoms vary, but generally, clinical depression is characterized by: Persistent… Read More
News | November 9, 2020
Last week, Srinivas Rao, MD, Chief Scientific Officer of ATAI Life Sciences, took to the stage alongside other leaders in psychedelic medicine at the 2019 Mapping the Mind conference in Toronto. The conference, which featured speakers like Dr. David Nichols, founding president of the Heffter Insitute, and Dr. Matthew Johnson, associate director of the… Read More
Articles | November 8, 2020
Gender greatly influences the power that males and females have over socio-economic factors that influence their mental health, social position… Read More
Articles | November 8, 2020
We’re social creatures: We not only desire interaction with others but actually need it. Contact with others… Read More
Articles | October 27, 2020
ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. (“Neuronasal”) has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has… Read More
Articles | October 9, 2020
Depression is today’s most prevalent mental health disorder and the leading cause of disability worldwide. Painful both mentally and physically,… Read More
Articles | August 25, 2020
Just weeks after the U.S. Food and Drug Administration approved approved Johnson & Johnson’s ketamine-like nasal spray for depression, a group of European technology investors just got together for the largest-ever private financing round for a psychedelic medicine biotech company, ATAI. … Read More
Articles | August 25, 2020
A couple days ago, ATAI Life Sciences, a biotech company developing psychedelic medicines for a variety of mental health indication, announced that it had raised $24 million in a convertible note financing round. … Read More
Articles | August 25, 2020
For years, the biggest push in psychedelic drug development has been around MDMA, a party drug long thought to have potential benefits for patients with PTSD. Rick Doblin, for years psychedelic therapy’s most prominent advocate and fundraiser, and his non-profit, MAPS, have raised millions to advance clinical trials, most recently… Read More
Articles | August 24, 2020
Viridia, a new company, is a wholly-owned subsidiary of ATAI Life Sciences AG, a global biotech platform. The company will generate multiple DMT products “based on alternative routes to intravenous administration.” This is a common method for giving DMT. Ultimately, Viridia will leverage ATAI Life Science’s drug development… Read More
JOIN THE ATAI #INSIGHTNETWORK